This article is more than 5 years old. Information may no longer be current.

Rutgers Cancer Institute appoints co-program leader

Issue: July 25, 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Stephen K. Burley, MD, DPhil, has been named co-program leader of the cancer pharmacology research program at Rutgers Cancer Institute of New Jersey.

Burley is director of the Center for Integrative Proteomics Research, founding director of the Institute of Quantitative Biomedicine, director of the Research Collaboratory for Structural Bioinformatics Protein Data Bank, and a professor of chemistry and chemical biology at Rutgers University.

Stephen K. Burley

“Dr. Burley’s presence brings a wealth of insight into protein structure and drug discovery that will greatly inform precision medicine oncology, as well as many other program areas at Rutgers Cancer Institute,” Eileen White, PhD, Rutgers Cancer Institute’s deputy director and associate director for basic science, said in a press release.

Burley will work with co-program leader X.F. Steven Zheng, PhD, a professor at Rutgers Robert Wood Johnson Medical School, to develop more effective cancer treatments through the discovery of new anticancer agents and strategies.